Review Article
Comprehensive analysis of COVID-19 vaccines: safety
characteristics, and post-immunization adverse events based on contemporary
global evidence
Análisis detallado de las vacunas contra la COVID-19:
características de seguridad y efectos adversos tras la vacunación según la
evidencia mundial actual
Ali Adel Dawood1* ORCID:
https://orcid.org/0000-0001-8988-5957
Zeyad Thonoon Al-Rrassam2 ORCID: https://orcid.org/0000-0002-9014-976X
Mahmood Abduljabbar Al-Tobje3 ORCID:
https://orcid.org/0009-0007-1402-0749
1 Department
of Anatomy, Al-Batool College of Medicine, University of Mosul, Mosul, Iraq.
2 Department
of Medical Physics, College of Science, University of Mosul, Mosul, Iraq.
3 Department
of Biology, College of Science, University of Mosul, Mosul, Iraq.
Corresponding author: aad@uomosul.edu.iq
ABSTRACT
A solution to the COVID-19 vaccine production and rapid deployment is an
unparalleled step in medical history. This review has examined evidence of the
effectiveness and safety of COVID-19 vaccines in vaccine platforms including
mRNA (Pfizer-BioNTech, Moderna),
adenoviral vector (AstraZeneca, Johnson and Johnson), whole inactivated virus (Sinovac, Sinopharm), recombinant
protein subunit (Novavax), and Cuban developed
vaccines, conjugate and recombinant protein subunit platforms (Soberana, Abdala), which are important contributors to
vaccine diversity and equity. These vaccines show high effectiveness in
preventing severe diseases, hospitalization, and death in different groups of
people. However, they are associated with a spectrum of adverse reactions
ranging in severity from mild to serious. Common expected reactions include local
injection site pain, erythema, and swelling, accompanied by systemic symptoms
such as fever, fatigue, myalgia, and headache, which are generally transient
and self-limited. Rare but serious complications have been identified and
characterized, most notably myocarditis and pericarditis predominantly in young
males after mRNA vaccination, thrombosis with thrombocytopenia syndrome after
adenoviral vector vaccines, Guillain-Barré syndrome, and various autoimmune
manifestations. Reproductive health concerns, including transient menstrual
irregularities, have also been reported, though fertility and pregnancy
outcomes data are reassuring. Global pharmacovigilance systems have
consistently demonstrated that serious adverse events are rare compared to the
substantial protective benefits of vaccination. This review also discusses
long-term safety considerations, special population profiles, and the critical
role of transparent risk communication in maintaining public confidence in
vaccination programs.
Keywords: vaccine safety; adverse event; immunization; pharmacovigilance.
RESUMEN
La solución para la producción y el rápido
despliegue de las vacunas contra la COVID-19 fue un hito sin precedentes en la
historia de la medicina. En esta revisión se ha analizado la eficacia y la
seguridad de las vacunas contra la COVID-19 en diversas plataformas, entre las
que se incluyen las de ARNm (Pfizer-BioNTech,
Moderna), las de vector adenoviral (AstraZeneca,
Johnson & Johnson), las de virus inactivado completo (Sinovac,
Sinopharm), las de subunidades proteicas
recombinantes (Novavax), y las vacunas desarrolladas
en Cuba —plataformas de conjugado y de subunidades proteicas recombinantes
(Soberana, Abdala)—, que han contribuido de manera importante a la diversidad y
la equidad en materia de vacunas. Estas vacunas han demostrado una alta
eficacia a la hora de prevenir la enfermedad grave, la hospitalización y la
muerte en diferentes grupos de población. Sin embargo, se han asociado a una
serie de reacciones adversas, cuya gravedad varía de leve a grave. Entre las
reacciones comunes esperadas se incluyen dolor local, eritema e hinchazón en el
lugar de la inyección, acompañados de síntomas sistémicos como fiebre, fatiga,
mialgia y cefalea, que suelen ser transitorios y autolimitados. Se han
identificado y caracterizado complicaciones poco frecuentes, pero graves, entre
las que destacan la miocarditis y la pericarditis —predominantemente en hombres
jóvenes tras la vacunación con ARNm—, el síndrome de trombosis con
trombocitopenia tras las vacunas con vector adenoviral,
el síndrome de Guillain-Barré y diversas manifestaciones autoinmunes. También
se han notificado problemas de salud reproductiva, incluidas irregularidades
menstruales transitorias, aunque los datos sobre la fertilidad y los resultados
del embarazo son tranquilizadores. Los sistemas mundiales de farmacovigilancia
han demostrado de forma sistemática que los efectos adversos graves son poco
frecuentes en comparación con los importantes beneficios protectores de la
vacunación. En esta revisión también se analizan las consideraciones relativas
a la seguridad a largo plazo, los perfiles de poblaciones especiales y el papel
fundamental que desempeña la comunicación transparente de los riesgos a la hora
de mantener la confianza del público en los programas de vacunación.
Palabras clave: seguridad
de las vacunas; evento adverso; inmunización; farmacovigilancia.
Received: March
11, 2026
Accepted:
October 28, 2026
Introduction
COVID-19, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), appeared at the end of 2019 and rapidly evolved into a global
pandemic of unprecedented scale, profoundly affecting human society, healthcare
systems, and the trajectory of scientific research.(1) According to
the latest figures as of 2024, more than 777 million confirmed cases and over 7
million deaths have been reported worldwide; however, given widespread
underreporting and limited testing capacity in many regions, actual statistics
are expected to be substantially higher.(2)
The traditional vaccine development cycle normally takes 10 to 15 years
between inception research up to regulatory approval including preclinical
trials, multiple phases of clinical trials, scale-up manufacturing and
regulatory processes.(3,4)
Nevertheless, the catastrophic toll of the COVID-19 pandemic necessitated
unprecedented acceleration. This was achieved through parallel rather than
sequential development phases, massive public and private financial investment
exceeding 100 billion dollars worldwide, elimination of financial risk for the
pharmaceutical industry, and expedited regulatory evaluation without
compromising scientific rigor.(4) The result was emergency use
authorization of the first COVID-19 vaccines within eleven months of the
release of the viral genetic sequence an extraordinary accomplishment
demonstrating the capacity of modern vaccine science and international
scientific cooperation.
Several distinct vaccine platforms were designed and implemented. The
Pfizer-BioNTech (BNT162b2) and Moderna
(mRNA-1273) vaccines are mRNA-based, delivering synthetic messenger RNA
encoding the spike protein via lipid nanoparticles.(5,6)
The Oxford-AstraZeneca (ChAdOx1 nCoV-19), Johnson & Johnson (Ad26.COV2. S),
and Sputnik V vaccines use non-replicating adenoviral vectors to deliver
genetic instructions for spike protein production.(7) Inovac (CoronaVac) and Sinopharm (BBIBP-CorV) are
developed based on well-established and established platforms of chemically
inactivated whole virus particles respectively; Novavax
(NVX-CoV2373) is based on a platform of recombinant purified spike protein and
the Matrix-M adjuvant. Cuba also created vaccines of its own, such as Soberana and Abdala, which were extensively used in the
country and thus are significant in the global diversity and equity of vaccines.(8,9)
As of December 2024, more than 13.5 billion vaccine doses have been
administered worldwide, but enormous coverage disparities exist between
countries and regions. High-income nations achieved vaccination rates exceeding
80 % of their populations, while most low-resource nations were unable to
vaccinate more than 20 % of their populations due to supply chain constraints,
infrastructure limitations, vaccine hesitancy, and geopolitical factors.(9)
The rapid development and widespread deployment of COVID-19 vaccines,
while constituting a landmark achievement in public health, generated
significant controversy regarding safety, efficacy, and adverse effects. This
discussion emerged against the background of unparalleled information
saturation and misinformation via social media platforms, politicization of
individual health, historical distrust of medical services by some groups, and
reasonable scientific skepticism about the safety of new vaccine technology in
the long term.(10)
As a counter to this, the healthcare system across the globe has
developed extensive pharmacovigilance programs that entail the collaboration
between passive surveillance programmes, including
the U.S. Vaccine Adverse Event Reporting System (VAERS), and active
surveillance programmes, including the Vaccine Safety
Datalink (VSD), and the multilateral efforts in this context through the WHO
Global Advisory Committee on Vaccine Safety.(11) These systems
allowed quick recognizing of safety signals and prompt changes in
recommendations on vaccinations.
The present review is a synthesis of the available evidence regarding
COVID-19 vaccine adverse events that have been reported in peer-reviewed
literature since 2022 that includes real-world safety information on
first-generation vaccines and variant-specific vaccine modifications and
maturation of global pharmacovigilance systems. It aims at equipping
clinicians, public health practitioners, and policymakers with a holistic,
evidence-based profile of the benefits and risks of available COVID-19 vaccines.(11)
Methods
Literature search strategy
The search of the literature was systematic in PubMed, Scopus, Web of
Science, and Cochrane Library concerning the articles published between January
2022 and December 2024. The search terms were the following: COVID-19 vaccines,
SARS-CoV-2 immunization, vaccine adverse events, vaccine safety, mRNA vaccines,
viral vectors vaccines, and the names of individual adverse events such as
myocarditis, thrombosis, thrombocytopenia, neurological complications, and
autoimmune reactions.(12)
Inclusion and exclusion criteria
The inclusion criteria included peer-reviewed original research
articles, systematic reviews, and meta-analyses; publications that reported
adverse events following the COVID-19 vaccination; large-scale population-based
surveillance studies; randomized controlled trials containing safety data; literature
published in English in 2022 to 2024.
The exclusion criteria included case reports of less than five patients,
preprint articles that had not undergone peer review, and commentaries and
editorials that did not include original data and studies that included an
ambiguous methodology or inadequate data reporting.(5,13)
Data extraction and synthesis
Information was obtained regarding type of vaccine, type and frequency
of adverse events, demographics of patient, level of severity, and time
association with the vaccination. Since study designs and the populations of
the studies under analysis are highly heterogeneous, the narrative synthesis
approach was chosen rather than formal meta-analysis.(13)
The Cochrane Risk of Bias tool of randomized studies and Newcastle-Ottawa Scale
of observational studies were used to determine the quality of studies.
Common and expected adverse events
Local reactions at the injection site
Local reactions at the injection site are the most frequently reported
adverse events following COVID-19 vaccination, affecting between 50% and 90% of
vaccine recipients depending on the specific vaccine and dose number. Patients
who receive mRNA vaccines typically experience pain at the injection site after
receiving the vaccine, with 70-90% reporting such pain, and the pain being more
often and more severe after the second dose of a two-dose primary vaccine.(14)
The pain typically peaks within 24-48 hours’ post-vaccination and resolves
within 3-5 days without specific treatment.
Erythema and swelling at the injection site occur less frequently,
affecting approximately 10-20% of recipients. In a subset of cases, delayed
large local reactions have been documented, characterized by redness and
swelling exceeding 10 cm in diameter, sometimes termed "COVID arm" or
"Moderna arm" due to their higher frequency
with the Moderna vaccine.(15) These
delayed reactions typically appear 4-11 days after vaccination and resolve
spontaneously; they are not indicative of bacterial cellulitis and do not
require antibiotic treatment.(15)
Axillary or cervical lymphadenopathy ipsilateral to the vaccination site
has been reported in approximately 10-15% of mRNA vaccine recipients, typically
appearing 1-4 days’ post-vaccination and resolving within 1-2 weeks.
Importantly, this reactive lymphadenopathy may be misinterpreted as malignant
involvement on breast imaging and other radiological examinations. Current
evidence-based guidance recommends deferring routine mammography or lymph node
imaging by 4-6 weeks following vaccination whenever clinically feasible to
avoid false-positive findings.(16)
Systemic reactions
Post-vaccination systemic symptoms are common and reflect the normal
immunological activation triggered by vaccine administration. The most
frequently reported systemic symptom is fatigue, occurring in 40-70% of
recipients, with higher frequency following the second dose of two-dose regimens.(17) This is a mild to
moderate fatigue which usually ends in 2-4 days. Common vaccine side effects
are headache, fatigue, myalgia and fever. Around 30-60% of recipients
experience a headache, which generally resolves within 2-3 days, whereas 40-70%
have fatigue and 30-50% experience myalgia, both of which are generally
short-lived and self-limited, and fever is seen in 10-40% of the recipients,
and is generally short-lived and self-limited.(17)
Myalgia and arthralgia are experienced by 30-50 percent of vaccine
recipients, and it is associated with general muscle pains or joint pain that
may occur up to 24 hours after the vaccine, and may end in 2-4 days. Although
there is much variation in the presence of fever depending on the vaccine platform,
dose number and age group, fever is reported by 10-40% of vaccine recipients
and is more common with mRNA vaccines than with viral vectors or inactivated
virus vaccines and second doses than first doses.(18) Younger adults
(ages 18-55) tend to have a higher rate of fever after vaccination than older
adults (≥65 years). This age difference is attributed to the increased
reactogenicity of immunity response in younger populations versus the less
reactogenic response in the older population which is associated with lower
rates of post-vaccination fever.(19)
Cardiovascular complications
Myocarditis and pericarditis
After mRNA COVID-19 vaccination, an important vaccine safety signal was
identified as myocarditis (inflammation of the myocardium) and pericarditis
(inflammation of the pericardium) in adolescent and young adult males.(20)
A series of population-based studies in various countries showed that there
were regularly high rates of myocarditis after an mRNA vaccination compared
with prior background rates, and that the most significant rate occurred after
the second dose in the initial series.
The VAERS and the VSD showed a range of 12-30 per 1,000,000 second doses
of mRNA vaccine in males aged 12-29 years, many times more than background
rates. The rates of 50-70 cases per million second doses were recorded among
the most at risk population in males aged 16-19 years, and the most critical
period was 3-5 days after the vaccination. In females, risk was significantly
reduced at about 2-4 cases/million doses. The risk level went down
significantly with age, and people above 40 years had only slightly higher
rates than the baseline.(21,22)
Figure 1 shows a more detailed age and sex-stratified incidence of myocarditis
after mRNA vaccination, which clearly shows that the risk is significantly
higher in young males but decreases with age. The data for Figure 1 were
gathered from the publicly available surveillance reports from the VAERS and the
VSD.(23,24) The Figure 1 was
compiled by the authors based on aggregated incidence figures, by age and sex.
Fig. 1. Age and sex-stratified
myocarditis risk following mRNA vaccination.
The Moderna vaccine (mRNA‑1273) was associated with a
higher incidence of myocarditis compared to the Pfizer‑BioNTech vaccine (BNT162b2), which
may be related to the larger mRNA dose (100 µg versus 30 µg) or differences in lipid nanoparticle
composition.(25) The clinical picture of vaccine-associated
myocarditis is usually characterized by chest pain that appears 2-5 days after
the vaccination that is sometimes characterized as sharp or pressure-like. Most
cases do have electrocardiographic abnormalities most frequently ST-segment
elevations implying acute myocardial injury. Most of the diagnosed cases show a
high level of cardiac troponin levels, which are biomarkers of myocardial injury.(20,26)
The mechanisms proposed to cause vaccine-associated myocarditis are not
fully characterized but probably an immune-mediated injury as SARS-CoV-2 virus
or vaccine mRNA has not been identified in cardiac biopsies. The suggested
mechanisms are molecular mimicry of spike protein epitopes with cardiac
proteins, overproduction of inflammatory cytokines after vaccination, and
direct action of lipid nanoparticle components on toll-like receptors.(26)
The vaccine-associated myocarditis prognosis is typically positive as
compared to viral myocarditis or COVID-19 infection-related myocarditis. Most
of the cases are mild and moderate in nature and it is only to monitor and not
to give aggressive treatment that patients have to be hospitalized. Subsequent
studies have shown that the majority of patients experience complete or almost
complete resolution of both cardiac abnormalities and symptoms in 3-6 months.
Comparative studies have shown that, in all age groups, the risk of myocarditis
after SARS-CoV-2 infection is significantly higher than after vaccination.
Furthermore, infection‑related myocarditis has been correlated with
the more serious clinical symptoms and poor prognosis.(27)
Thrombosis with thrombocytopenia syndrome (TTS)
Adenoviral vaccine COVID-19 vaccines, most commonly the AstraZeneca
(ChAdOx1 nCoV-19) and Johnson and Johnson (Ad26.COV2. S) vaccines, were found
to cause a rare but clinically significant adverse effect called thrombosis
with thrombocytopenia syndrome (TITS), also known as vaccine induced immune
thrombotic thrombocytopenia (VITT).(28,29) Incidences differ by age
and sex with rates estimated to be 1-2 cases in every 100,000 AstraZeneca doses
and 1-3 cases in every million J&J doses. The risk is significantly greater
in younger persons and women who are less than 50 years old specifically where
the risks of about 10-15 cases per million doses have been reported and the
risk is relatively low in older populations.(30)
TTS normally occurs 7-14 days after the vaccination with extreme
persistent headache, visual or localized neurological disorders, stomach pains,
and swelling of limbs.(31) Among the findings in the laboratory,
there is marked thrombocytopenia, increased D-dimer (>4,000 ng/mL), and
positive platelet factor 4 (PF4) antibodies-pathognomonic of vaccine-associated
TTS in patients who had no previous exposure to heparin. The mechanism
pathophysiology entails the anti-PF4 antibody-mediated immunologic complexes
interacting platelets through Fc-receptors, which stimulates platelet
aggregation and thrombocytopenia and is paradoxical, as it induces a prothrombotic
condition.(30) This is a
pathological process, with important therapeutic implications, particularly
avoiding the use of heparin. Intravenous immunoglobulin and non‑heparin anticoagulants (argatroban or fondaparinux) are recommended; plasma
exchange should be used in refractory cases.(32)
The mortality rate of TTS is approximately 20-40 % and highest in the cerebral
venous sinus thrombosis. This has led to several countries substantially
changing their vaccine policies.(30)
Neurological complications
Guillain - Barré syndrome
Guillain-Barré syndrome (GBS) is a rare acute inflammatory demyelinating
polyneuropathy which has been reported at a slightly increased rate after
COVID-19 adenoviral vector vaccines, primarily the Johnson & Johnson
Ad26.COV2.S vaccine. Population-based surveillance
studies identified a small rise in the incidence of GBS, around 1-2 per million
doses, over and above the background rate.(33) These clinical
features are progressive ascending weakness that starts in the lower
extremities, sensory, and areflexia, and in some cases, respiratory muscle
impairment leading to the need of mechanical ventilation. Therapy is by
intravenous immunoglobulin or therapeutic plasma exchange and most patients
show great improvements in their neurological recovery but some deficits may be
left behind.(34)
An equally significant contextual fact is that comparative
epidemiological research has always revealed that the risk of GBS due to
COVID-19 itself is significantly greater than that due to vaccination, and the
rates related to infections are always 5-10 times higher than those related to
vaccination. Such a risk-benefit orientation is crucial to clinical counseling
and health education to the population.(35)
Cerebral venous sinus thrombosis
The development of cerebral venous sinus thrombosis (CVST), which is a
rare type of stroke that occurs in response to thrombosis of the cerebral
venous drainage system, was identified as a very worrying presentation of TTS,
following adenoviral vectors vaccination. CVST is characterized by acute and
unremitting headache, optical and neurological disturbances, seizures, local
cerebral impairments, and confusion.(29)
CVST and thrombocytopenia combined should immediately raise the question of TTS.
Specialized non-heparin anticoagulation and neurocritical care support and
extensive attention to clinical deterioration are required in the management.
Neurological manifestations other than neuropathy
Other neurological side effects reported following COVID-19 vaccination
include Bell's palsy (facial nerve paralysis), transverse myelitis
(inflammation of the spinal cord) and sensory disturbances. There was a slight
increase in the number of cases of Bell's palsy in early clinical trials
compared to placebo. Later, large-scale surveillance studies, however, did not
support this finding, with the overall rates being similar to those of the
unvaccinated population.(36)
Autoimmune and inflammatory complications
Immune thrombocytopenia
Immune thrombocytopenia (ITP), also referred to as isolated
thrombocytopenia, is an autoimmune condition characterized by antibody‑mediated platelet
destruction. Rare cases have been reported following COVID‑19 vaccination across
different platforms. Unlike TTS, the ITP manifests as isolated thrombocytopenia
without thrombotic complications. The estimated incidence is approximately 1-2
cases per 100,000 vaccinations, which is broadly consistent with background
population rates. Management strategies include observation in mild cases,
while corticosteroids, intravenous immunoglobulin, and thrombopoietin receptor
agonists are recommended for more severe presentations. With appropriate
treatment, clinical outcomes are generally favorable.(37)
Autoimmune hepatitis
Rare adverse effects that have been described after COVID-19
vaccination, specifically after adenoviral vectors vaccine include autoimmune
hepatitis, which presents itself as hepatocellular injury with increased liver
enzymes and autoantibodies. Jaundice, fatigue and biochemical hepatitis
evidence were clinical manifestations. Immunosuppressive therapy using
corticosteroids was usually effective in cases, and majority of the patients
had biochemical remission. The pathophysiology suggested is autoimmune reactivity
of immune dysregulation caused by the vaccine to hepatic antigens.(38,39)
Thyroid disorders
COVID-19 vaccination is related to thyroid dysfunction but a number of
published case series and surveillance reports describe it as either subacute
thyroiditis or exacerbations of underlying autoimmune thyroid disease,
including Graves' disease and Hashimoto's thyroiditis.(40) Subacute
thyroiditis has symptoms of anterior neck pain, fever and biphasic thyroid
functional abnormalities, first hyperthyroidism, then transient hypothyroidism
and the subsequent euthyroidism in most instances.
There are mild cases where the management involves the use of non-steroidal
anti‑inflammatory drugs or moderate to severe disease where corticosteroids are
used and most cases are self-limiting and resolved in a few months.(41)
Reproductive health concerns
Menstrual irregularities
There has been reports that a large percentage of women experienced
changes in their menstrual cycle after COVID‑19 vaccination, such as a change
in the length of the cycle, flow changes, and increased dysmenorrhea. Large
cohort studies have found that 25-40% of menstruating women reported some type
of menstrual problem, including: starting menstruation earlier than usual;
starting menstruation later than usual; having heavier periods; having lighter
periods; or having more menstrual pain. Importantly, these changes tended to be
temporary, with most women experiencing the return of their pre‑vaccination periods within
1-2 cycles.(42)
These menstrual changes are believed to be due to the transient immune
activation that occurs in the hypothalamic-pituitary-ovarian axis, an endocrine
control system that controls the menstrual cycle. Notably, these changes seem
to be reversible and have not been linked to any long‑term reproductive impairment.(43)
Fertility and pregnancy outcomes
In the strict sense of the word, it should be noted that fertility and
pregnancy outcomes are not considered an adverse event; however, they have been
a significant concern of the public, the source of vaccine hesitancy, and of
clinical interest when counseling pregnant women about immunizations.
There has been no scientific evidence that vaccines against COVID‑19 will affect fertility.
The first report of cross‑reactivity between SARS‑CoV‑2 spike protein and
syncytin‑1 has been definitively rejected. The results of large prospective
cohort studies have shown that there are no differences in fertility indicators
between vaccinated and unvaccinated people. Research on in-vitro fertilization
(IVF) outcomes has shown that there is no effect on ovarian reserve,
fertilization rates, embryo quality or implantation.(44)
The male fertility parameters (sperm count, motility and morphology) were also
not affected. In addition, hundreds of thousands of women were followed and
there was no higher risk of miscarriage, stillbirth, premature delivery or
birth defects among women who were vaccinated during pregnancy than among those
who were not. Important, vaccination during pregnancy has been proven to
generate protective antibodies that pass on to the fetus and newborn, and all
major medical bodies recommend vaccination against COVID-19 in pregnancy.(45)
Long-term safety considerations
Duration of safety monitoring
Unlike conventional vaccine development during which long-term safety
data accumulate over years before mass deployment, COVID-19 vaccines were
authorized under emergency conditions.(21) Nevertheless, several
observations provide reassurance: mRNA degrades within days without genetic
modification; immune responses mirror those from natural infection; historical
vaccine data consistently show serious adverse events appear within
weeks-to-months post-vaccination rather than years; and ongoing surveillance
now encompasses billions of vaccinated individuals with follow-up periods
extending to 2-3 years, without identifying systematic increases in serious
adverse events beyond those already characterized.(21)
Risk of immune system dysregulation
Theoretical concerns about potential long-term immune system
dysregulation following COVID-19 vaccination including increased susceptibility
to infectious diseases or autoimmune conditions have been systematically
investigated. Available evidence does not demonstrate any signs of generalized
immune suppression, elevated infection rates, or compromised vaccine responses
to other pathogens in vaccinated populations. Ongoing surveillance of
autoimmune disease development has not revealed systematic increases in
autoimmune disease incidence beyond expected baseline levels.(18)
Cancer risk considerations
Circulating claims about potential carcinogenic effects of COVID-19
vaccines lacked any biological plausibility and have been extensively
investigated and refuted. mRNA vaccines do not carry out any biological
processes associated with carcinogenesis, as the mRNA does not integrate into
the genome, does not encode oncoproteins, and does not persist beyond days in
cells. Large-scale pharmacovigilance data have not identified any evidence of
increased cancer incidence rates in vaccinated populations compared to
unvaccinated controls or expected baseline rates.(46)
The overall results of a quantitative comparison between major adverse
outcomes rates with COVID-19 infection and vaccination per million individuals
exposed shows the overwhelming advantage of vaccination in all major categories
of complications using a logarithmic scale to show the vast range of values
(Fig. 2). The data for Figure 2 were obtained from published population-based
comparisons of adverse event rates after COVID‑19 infection and vaccination.(25,28,47,48,49)
Fig. 2. Risk-benefit analysis:
COVID-19 disease and vaccination complications.
Special populations
Pediatric populations
Vaccination of children and adolescents against COVID-19 generated
substantial public debate, reflecting the generally milder clinical course of
COVID-19 in this age group and concerns particularly about myocarditis risk
with mRNA vaccines. Extensive clinical trials and post-authorization
surveillance data demonstrated that vaccines are both safe and immunogenic
across pediatric age groups, though adverse event profiles vary by age.(50)
Children aged 5-11 years exhibited reduced reactogenicity and substantially
lower myocarditis rates compared to adolescents, attributable in part to use of
a lower vaccine dose (10 μg for the Pfizer vaccine).
Male adolescents aged 12-17 years represent the highest-risk demographic for
vaccine-associated myocarditis, necessitating individualized benefit-risk
assessment considering local COVID-19 epidemiology and individual health factors.(49,50)
Immunocompromised individuals
Immunocompromised individuals including solid organ transplant
recipients, patients with hematological malignancies, and individuals receiving
immunosuppressive therapy are among those at greatest risk for severe COVID-19
outcomes and therefore stand to derive considerable benefit from vaccination.
COVID-19 vaccination in these populations is generally safe, with adverse event
rates comparable to or lower than those observed in immunocompetent individuals
and no evidence of increased serious complications.(21) However,
vaccine-induced immune responses may be attenuated due to underlying immune
dysfunction or the effects of immunosuppressive medications, often
necessitating additional primary series doses and earlier booster vaccination.(51)
Elderly populations
Elderly populations bear the greatest burden of severe COVID-19 disease
and represent the highest-priority group for vaccination. The safety profile of
COVID-19 vaccines in older adults is favorable, characterized by reduced
reactogenicity compared to younger recipients, likely reflecting age-related immunosenescence with attenuated innate immune activation
following vaccination. Common adverse events such as injection site pain,
fatigue, and fever occur less frequently and with lesser severity in older
adults. The benefit-risk calculation for COVID-19 vaccination is overwhelmingly
favorable in elderly populations, given their disproportionate risk for
hospitalization, intensive care admission, and mortality from COVID-19 infection.(23)
Global pharmacovigilance systems
The world-wide distribution of COVID-19 vaccines demanded unprecedented
collaboration of safety surveillance in the varied healthcare systems. Several
complementary surveillance methods were put in place: passive surveillance
(VAERS, in the US, Yellow Card in the UK), active surveillance (VSD, Clinical
Immunization Safety Assessment project), and the international coordination
(the WHO Global Vaccine Safety Initiative). These platforms showed a very high
level of responsiveness; regulatory agencies have changed recommendations
within weeks of identifying safety signals, such as age-based restrictions on
adenoviral vectors vaccines because of TTS risk, bias in mRNA vaccine
recommendations in younger males because of concerns about myocarditis, and
clinical guidance on how to identify and manage rare vaccine-associated
conditions. The pharmacovigilance of COVID-19 vaccines has produced insights
and infrastructure gains that can advance the future of safety monitoring of vaccines.(21,46)
Comparative risk-benefit analysis
Quantitative risk comparisons
The related risks of COVID-19 infection significantly and uniformly
significantly outweigh the risks related to vaccination in the case of
virtually adverse events related to COVID-19 vaccines. Compared to vaccination,
myocarditis is much higher after COVID-19 infection in all ages and both sexes,
and myocarditis due to infection is generally more severe in clinical
presentation and poorer prognosis than myocarditis due to vaccination.
Likewise, thrombotic events such as CVST, deep vein thrombosis, and pulmonary
embolism are more frequently observed as a result of COVID-19 infection
compared to vaccination.(52)
Neurological events, including GBS, encephalitis, and stroke, and
autoimmune events such as ITP, myocarditis and multisystem inflammatory
syndromes, occur far more frequently in people who have contracted the virus
COVID-19. Infection is more likely to cause these conditions than vaccination.
Most importantly, the risks associated with COVID‑19 infection are high;
however, the risks associated with vaccination are very small, and most
benefits of vaccination are found in older adults and those at higher risk.(35,52)
Population-level benefits
The COVID-19 vaccination programs avoided the occurrence of millions of
hospitalizations and deaths around the world. Studies on epidemiological
modeling estimated that COVID-19 vaccination averted approximately 2.5 million
deaths worldwide during 2020-2024 (sensitivity range 1.4-4.0 million),
corresponding to about 15 million life-years saved. The benefits of vaccination
to society were far more than direct effects on health, and involved
significant economic benefits in terms of health burden saved to the healthcare
system, workforce productivity, and the ability to resume educational, social,
and economic activities that had been devastated by the pandemic.(53)
Future directions
The current development of vaccines is expected to enhance resistance
against new variants, minimize reactogenicity, and ease their delivery. Newer
strategies involve modified mRNA preparations with less inflammatory reactions,
pan-coronavirus vaccines that provide wider cross-variant coverage, and
intranasal preparations of the mucosa. Insight into the underlying mechanism of
the current adverse events will provide a direct input to the development of
safer new generation vaccines.(54) Innovations in pharmacogenomics
could potentially provide an opportunity to adopt a more individual approach to
vaccination, determining which individuals are at a high risk due to genetic or
immunological factors to certain adverse events and personalizing selection of
vaccines or changing monitoring regimens. The continued safety of both existing
and future vaccines will require strengthening the pharmacovigilance
infrastructure across the whole world with uniformity in the definition of
adverse events, enhancing integration of electronic health records to
facilitate automated detection of signals, and increasing the range of data
sharing by countries worldwide.(55).
Conclusions
This overview shows that the benefit-risk ratio is clearly positive for
all the approved COVID-19 vaccines in most of the populations. The benefits of
preventing severe illness, hospitalization and death far outweigh the reported
risks. Common side effects include local injection site reactions, mild fever,
fatigue and myalgia, which are all transient immune reactions and disappear
within days. Although a small number of rare and more severe adverse events
have been described, such as myocarditis, TTS, GBS, and autoimmune problems,
there is no evidence of the incidences of these events being significantly
higher than they are when COVID‑19 itself occurs. The unprecedented evidence
of real-world safety that has been obtained during rollout of vaccines across the
world underscores the need for ongoing pharmacovigilance. Future objectives are
to better understand the mechanisms underlying rare complications, establish
predictive markers for risk stratification, refine vaccine formulation and
achieve equitable global access.
References
1. Dawood A, Alnori HA-M. Tunicamycin
Anticancer Drug May Reliable to Treat Coronavirus Disease-19. Open Access Maced J Med Sci. 2020;8(T1):129-33. doi:
https://10.3889/oamjms.2020.4954.
2. ourworldindata.org [homepage on the Internet].
Oxford: Our World in Data; c2024-08. Available from:
https://ourworldindata.org/covid-vaccinations. (Access online: December 2025).
3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S,
et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15. doi:
https://10.1056/NEJMoa2034577.
4. Sadoff J, Gray G, Vandebosch
A, Cárdenas V, Shukarev G, Grinsztejn
B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S
Vaccine against Covid-19. N Engl J Med.
2021;384(23):2187-201. doi:
https://10.1056/NEJMoa2101544.
5. Tanriover MD, Doğanay
HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy
and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
Lancet. 2021;398(10296):213-22. doi:
https://10.1016/S0140-6736(21)01429-X.
6. Wagner CE, Saad-Roy CM, Morris SE, Baker RE, Mina MJ, Farrar J, et
al. Vaccine nationalism and the dynamics and control of SARS-CoV-2. Science.
2021;373(6562):eabj7364. doi:
https://10.1126/science.abj7364.
7. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and Efficacy of
NVX-CoV2373 Covid-19 Vaccine. N Engl J Med.
2021;385(13):1172-83. doi: https://10.1056/NEJMoa2107659.
8. Toledo-Romaní
ME, García-Carmenate M, Valenzuela-Silva C, Baldoquín-Rodríguez W, Martínez-Pérez M, Rodríguez-González
M, et al. Safety and efficacy of the two doses
conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous
three-dose combination with SOBERANA-Plus: a double-blind, randomised,
placebo-controlled phase 3 clinical trial. Lancet Reg Health Am. 2023;18:100423. doi:
https://10.1016/j.lana.2022.100423.
9. Más-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodríguez K. Cuban Abdala vaccine: Effectiveness
in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort
study. Lancet Reg Health Am. 2022;16:100366. doi: https://10.1016/j.lana.2022.100366.
10. Karikó K, Muramatsu
H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic
vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833-40. doi:
https://10.1038/mt.2008.200.
11. World Health Organization. Global Advisory Committee on Vaccine
Safety, 10 August 2021; Global Advisory Committee on Vaccine Safety, 15
December 2021. Wkly Epidemiol Rec. 2022;97(10):81-96.
Available from: https://www.who.int/publications/i/item/who-wer9710-81-96.(Access
online: December 2025).
12. Voysey M, Clemens SAC, Madhi
SA, Weckx LY, Folegatti PM,
Aley PK, et al. Safety and efficacy of the ChAdOx1
nCoV-19 vaccine (AZD1222) against SARS-CoV-2. Lancet. 2021;397(10269):99–111. doi: https://10.1016/S0140-6736(20)32720-3
13. Dawood AA, Dawood ZA. How will the second wave of the dreadful
COVID-19 be with the increasing number of the infected cases and mortality in
Iraq? Vacunas. 2021;22(2):114-8. doi:
https://10.1016/j.vacun.2020.09.007.
14. Baden LR, El Sahly HM, Essink
B, Kotloff K, Frey S, Novak R, et al. Efficacy and
Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J
Med. 2021;384(5):403-16. doi:
https://10.1056/NEJMoa2035389.
15. Blumenthal KG, Ahola C, Anvari S, Samarakoon U, Freeman EE. Delayed large local
reactions to Moderna COVID-19 vaccine: A follow-up
report after booster vaccination. JAAD Int. 2022;8:3-6.
doi: https://10.1016/j.jdin.2022.03.017.
16. Lehman CD, Lamb LR, D'Alessandro HA. Mitigating the Impact of
Coronavirus Disease (COVID-19) Vaccinations on Patients Undergoing Breast
Imaging Examinations: A Pragmatic Approach. AJR Am J Roentgenol.
2021;217(3):584-6. doi: https://10.2214/AJR.21.25688.
17. Shinde V, Bhikha S, Hoosain
Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine
against the B.1.351 Variant. N Engl J Med.
2021;384(20):1899-909. doi:
https://10.1056/NEJMoa2103055.
18. Chapin-Bardales J, Gee J, Myers T.
Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. JAMA. 2021;325(21):2201-2.
doi: https://10.1001/jama.2021.5374.
19. Menni C, Klaser
K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2
infection after vaccination in users of the COVID Symptom Study app in the UK:
a prospective observational study. Lancet Infect Dis. 2021;21(7):939-49. doi: https://10.1016/S1473-3099(21)00224-3.
20. Mevorach D, Anis E, Cedar N, Bromberg M,
Haas EJ, Nadir E. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in
Israel. N Engl J Med. 2021;385(23):2140-9. doi: https://10.1056/NEJMoa2109730.
21. Klein NP, Lewis N, Goddard K, Fireman B, Zerbo
O, Hansonet KE, et al. Surveillance for Adverse
Events After COVID-19 mRNA Vaccination. JAMA. 2021;326(14):1390–9. doi: https://10.1001/jama.2021.15072.
22. Oster ME, Shay DK, Su JR, Gee J, Creech
CB, Broder KR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19
Vaccination in the US From December 2020 to August
2021. JAMA. 2022;327(4):331-40. doi:
https://10.1001/jama.2021.24110.
23. Soiza RL, Scicluna C, Thomson EC. Efficacy
and safety of COVID-19 vaccines in older people. Age Ageing. 2021;50(2):279-83.
doi: https://10.1093/ageing/afaa274.
24. Chen JS, Alfajaro MM, Chow RD, Wei J,
Filler RB, Eisenbarth SC, Wilen CB. Non-steroidal
anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2
infection. J Virol. 2021;95(7):e00014-21.
doi: https://10.1128/JVI.00014-21.
25. Karlstad Ø, Hovi P, Husby
A, Härkänen T, Selmer RM, Pihlström
N, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23
Million Residents. JAMA Cardiol. 2022;7(6):600-12. doi: https://10.1001/jamacardio.2022.0583.
26. Bozkurt B, Kamat I, Hotez
PJ. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144(6):471-84. doi: https://10.1161/CIRCULATIONAHA.121.056135.
27. Patone M, Mei XW, Handunnetthi
L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risk
of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2
Infection by Age and Sex. Circulation. 2022;146(10):743-54. doi:
https://10.1161/CIRCULATIONAHA.122.059970.
28. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and
Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl
J Med. 2021;384(22):2124-30. doi: https://10.1056/NEJMoa2104882.
29. See I, Su JR, Lale
A, Woo EJ, Guh AY, Shimabukuro TT, et al. US Case
Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After
Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
JAMA. 2021;325(24):2448-56. doi: https://10.1001/jama.2021.7517.
30. Pavord S, Scully M, Hunt BJ, Lester W,
Bagot C, Craven B, et al. Clinical Features of Vaccine-Induced Immune
Thrombocytopenia and Thrombosis. N Engl J Med.
2021;385(18):1680-9. doi:
https://10.1056/NEJMoa2109908.
31. Greinacher A, Thiele T, Warkentin TE,
Weisser K, Kyrle PA, Eichinger
S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021;384(22):2092-2101. doi:
https://10.1056/NEJMoa2104840.
32. Klok FA, Pai M, Huisman MV, Makris M.
Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol.
2022;9(1):e73-e80. doi:
https://10.1016/S2352-3026(21)00306-9.
33. Woo EJ, Mba-Jonas A, Dimova
RB, Alimchandani M, Zinderman
CE, Nair N. Association of Receipt of the Ad26.COV2.S
COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021.
JAMA. 2021;326(16):1606-13. doi:
https://10.1001/jama.2021.16496.
34. Wiegers EJA, Jacobs BC. New insights in
the immune treatment of Guillain-Barré syndrome. Curr
Opin Neurol. 2025;38(5):471-7. doi:
https://10.1097/WCO.0000000000001408.
35. Patone M, Handunnetthi
L, Saatci D, Pan J, Katikireddi
SV, Razvi S, et al. Neurological complications after
first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med.
2021;27(12):2144-53. doi: https://10.1038/s41591-021-01556-7.
36. Ozonoff A, Nanishi
E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. Lancet Infect Dis.
2021;21(4):450-2. doi:
https://10.1016/S1473-3099(21)00076-1.
37. Welsh KJ, Baumblatt J, Chege
W, Goud R, Nair N. Thrombocytopenia including immune thrombocytopenia after
receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event
Reporting System (VAERS). Vaccine. 2021;39(25):3329-32. doi:
https://10.1016/j.vaccine.2021.04.054.
38. Bril F, Al Diffalha
S, Dean M, Fettig DM. Autoimmune hepatitis developing after coronavirus disease
2019 (COVID-19) vaccine: Causality or casualty? J Hepatol.
2021;75(1):222-4. doi:
https://10.1016/j.jhep.2021.04.003.
39. Vuille-Lessard É, Montani
M, Bosch J, Semmo N. Autoimmune hepatitis triggered
by SARS-CoV-2 vaccination. J Autoimmun. 2021;123:102710. doi:
https://10.1016/j.jaut.2021.102710.
40. Jafarzadeh A, Nemati M, Jafarzadeh S, Nozari
P, Mortazavi SMJ. Thyroid dysfunction following vaccination with COVID-19
vaccines: a basic review of the preliminary evidence. J Endocrinol Invest.
2022;45(10):1835-63. doi:
https://10.1007/s40618-022-01786-7.
41. Frangos S, Haralambous
H, Michael K, Economides PA. Subacute thyroiditis after the third dose of the
COVID-19 mRNA vaccine. Case report. Hell J Nucl Med. 2022;25(2):210-2. doi: https://10.1967/s002449912481.
42. Edelman A, Boniface ER, Benhar E, Han L, Matteson KA, Favaro C, et al. Association Between Menstrual Cycle Length and Coronavirus Disease 2019
(COVID-19) Vaccination: A U.S. Cohort. Obstet
Gynecol. 2022;139(4):481-9. doi:
https://10.1097/AOG.0000000000004695.
43. Morris RS. SARS-CoV-2 spike protein seropositivity from vaccination
or infection does not cause sterility. F S Rep. 2021;2(3):253-5. doi: https://10.1016/j.xfre.2021.05.010.
44. Zhang L, Sun X, Wang R, Ma F. Effect of COVID-19 vaccination on the
outcome of in vitro fertilization: A systematic review and meta-analysis. Front
Public Health. 2023;11:1151999. doi:
https://10.3389/fpubh.2023.1151999.
45. Magnus MC, Gjessing HK, Eide HN, Wilcox
AJ, Fell DB, Håberg SE. Covid-19 vaccination during
pregnancy and first-trimester miscarriage. N Engl J
Med. 2021;385(21):2008–10. doi:
https://10.1056/nejmc2114466.
46. World Health Organization. Report of the Meeting of the WHO Global
Advisory Committee on Vaccine Safety (GACVS), 8–9 June 2021. WHO Weekly
Epidemiological Record. 2021;96(29):421–8. Avalaible
at:
https://reliefweb.int/report/world/weekly-epidemiological-record-wer-23-july-2021-vol-96-no-29-pp-321-328-enfr.
(Access online: December 2025).
47. Hanson KE, Goddard K, Lewis N, Fireman B, Myers TR, Bakshi N, et al. Incidence of Guillain-Barré Syndrome After
COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Netw
Open. 2022;5(4):e228879. doi:
https://10.1001/jamanetworkopen.2022.8879.
48. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et
al. Safety of the BNT162b2 mRNA Covid-19 Vaccine
in a Nationwide Setting. N Engl J Med.
2021;385(12):1078-90. doi:
https://10.1056/NEJMoa2110475.
49. Pillay J, Gaudet L, Wingert A, Bialy L, Mackie AS, Paterson DI,
Hartling L. Incidence, risk factors, natural history, and hypothesised
mechanisms of myocarditis and pericarditis following covid-19 vaccination:
living evidence syntheses and review. BMJ. 2022;378:e069445.
doi: https://10.1136/bmj-2021-069445.
50. Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, et al. Epidemiology of Myocarditis and
Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario,
Canada. JAMA Netw Open. 2022;5(6):e2218505.
doi: https://10.1001/jamanetworkopen.2022.18505.
51. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A.
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N
Engl J Med. 2021;385(7):661-2. doi:
https://10.1056/NEJMc2108861.
52. Hippisley-Cox J, Patone
M, Mei XW, Saatci D, Dixon S, Khunti
K, et al. Risk of thrombocytopenia and thromboembolism after covid-19
vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
BMJ. 2021;374:n1931. doi:
https://10.1136/bmj.n1931.
53. Ioannidis JPA, Pezzullo AM, Cristiano A,
Boccia S. Global Estimates of Lives and Life-Years Saved by COVID-19
Vaccination During 2020-2024. JAMA Health Forum. 2025;6(7):e252223.
doi: https://10.1001/jamahealthforum.2025.2223.
54. Omersel J, Karas
Kuželički N. Vaccinomics
and Adversomics in the Era of Precision Medicine: A
Review Based on HBV, MMR, HPV, and COVID-19 Vaccines. J Clin Med.
2020;9(11):3561. doi: https://10.3390/jcm9113561.
55. World Health Organization. Global Vaccine Safety Blueprint 2.0
(GVSB2.0) 2021-2023. Geneva: WHO; 2021. Available from:
https://www.who.int/publications/i/item/9789240036963. (Access online: December
2025).
Conflict of interest
The authors declare that
there is no conflict of interest.
Author’s contributions
Ali Adel Dawood:
conceptualization, methodology, writing original draft, writing review and
editing, supervision.
Zeyad Thonoon
Al-Rrassam: data curation, writing review and
editing.
Abduljabbar Al-Tobje:
data curation, writing review and editing.
All authors have read and
agreed to the published version of the manuscript.
* Department of Anatomy,
Al-Batool College of Medicine, University of Mosul, Mosul, Iraq.